Hematologic and clinical features at presentation in patients with PMF according to their JAK2 V617F mutational status
| Feature . | JAK2 WT . | JAK2 V617F . | P . |
|---|---|---|---|
| No. | 59 | 127 | |
| Median age, y (range) | 57 (21-88) | 62 (21-90) | .47 |
| Median follow-up, mo (range) | 27 (1-185) | 29 (1-237) | .72 |
| Females, no. (%) | 18 (30.5) | 51 (40.1) | .23 |
| Median white blood cell count, ×109/L (range) | 7.70 (1.9-90.78) | 10.10 (3.01-16.15) | .009* |
| Median hemoglobin, g/L (range) | 106 (46-190) | 128.5 (54-180) | <.001* |
| Median platelets, ×109/L (range) | 251 (8.0-1488) | 386 (42-2011) | .02* |
| Blast >1, no. (%) | 16 (30.5) | 38 (29.9) | .89 |
| Median LDH, U/L (range) | 704 (197-2970) | 718 (120-2981) | .96 |
| Median CD34+ cell, % (range) | 0.25 (0.0-6.6) | 0.19 (0-34) | .65 |
| Median CD34+ cell, ×109/L (range) | 18.84 (0.0-3417) | 22 (0.3-800) | .77 |
| Median JAK2V617F allele burden (range) | — | 54 (5-100) | — |
| Splenomegaly >15 cm from LCM, no. (%) | 11 (18.6) | 26 (19.7) | .89 |
| Constitutional symptoms, no. (%) | 15 (25.4) | 38 (29.9) | .15 |
| Leukemia transformation, no. (%) | 6 (10.1%) | 9 (7.1) | .45 |
| Deaths, no. (%) | 8 (13.5) | 15 (11.8) | .64 |
| Lille score, no. (%) | |||
| 0 | 22 (37.2) | 80 (63.0) | .017* |
| 1 | 26 (44.0) | 38 (30.0) | |
| 2 | 11 (18.8) | 9 (7.0) | |
| IWG-MRT score, no. (%) | |||
| low | 18 (30.5) | 47 (37.0) | .60 |
| Intermediate-1 | 15 (25.5) | 32 (25.2) | |
| Intermediate-2 | 16 (27.1) | 20 (15.7) | |
| High | 10 (16.9) | 28 (22.1) |
| Feature . | JAK2 WT . | JAK2 V617F . | P . |
|---|---|---|---|
| No. | 59 | 127 | |
| Median age, y (range) | 57 (21-88) | 62 (21-90) | .47 |
| Median follow-up, mo (range) | 27 (1-185) | 29 (1-237) | .72 |
| Females, no. (%) | 18 (30.5) | 51 (40.1) | .23 |
| Median white blood cell count, ×109/L (range) | 7.70 (1.9-90.78) | 10.10 (3.01-16.15) | .009* |
| Median hemoglobin, g/L (range) | 106 (46-190) | 128.5 (54-180) | <.001* |
| Median platelets, ×109/L (range) | 251 (8.0-1488) | 386 (42-2011) | .02* |
| Blast >1, no. (%) | 16 (30.5) | 38 (29.9) | .89 |
| Median LDH, U/L (range) | 704 (197-2970) | 718 (120-2981) | .96 |
| Median CD34+ cell, % (range) | 0.25 (0.0-6.6) | 0.19 (0-34) | .65 |
| Median CD34+ cell, ×109/L (range) | 18.84 (0.0-3417) | 22 (0.3-800) | .77 |
| Median JAK2V617F allele burden (range) | — | 54 (5-100) | — |
| Splenomegaly >15 cm from LCM, no. (%) | 11 (18.6) | 26 (19.7) | .89 |
| Constitutional symptoms, no. (%) | 15 (25.4) | 38 (29.9) | .15 |
| Leukemia transformation, no. (%) | 6 (10.1%) | 9 (7.1) | .45 |
| Deaths, no. (%) | 8 (13.5) | 15 (11.8) | .64 |
| Lille score, no. (%) | |||
| 0 | 22 (37.2) | 80 (63.0) | .017* |
| 1 | 26 (44.0) | 38 (30.0) | |
| 2 | 11 (18.8) | 9 (7.0) | |
| IWG-MRT score, no. (%) | |||
| low | 18 (30.5) | 47 (37.0) | .60 |
| Intermediate-1 | 15 (25.5) | 32 (25.2) | |
| Intermediate-2 | 16 (27.1) | 20 (15.7) | |
| High | 10 (16.9) | 28 (22.1) |
— indicates not applicable; and IWG-MRT, International Working Group for Myelofibrosis Research and Treatment.
Statistically significant difference.